首頁 > 市場調查報告書 > 醫療設備

手術用器具

市場調查報告書

商品編碼

1845902

全球血管閉合裝置市場規模（按類型、訪問、最終用戶、區域範圍和預測）

Global Vascular Closure Devices Market Size By Type (Passive Approximators, Active Approximators), By Access (Femoral Access, Radial Access), By End User (Hospitals, Clinics), By Geographic Scope And Forecast

出版日期: 2025年09月23日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血管閉合裝置市場規模及預測

2024 年血管閉合裝置市場規模為 9.3558 億美元，預計到 2032 年將達到 16.9132 億美元，2026 年至 2032 年的複合年成長率為 6.80%。

血管閉合裝置 (VCD) 市場是醫療設備產業的一個細分市場，專注於開發和銷售用於導管插入後止血（即止血）的器械。血管造影術、血管成形術和其他介入心臟病學手術通常需要在股動脈或橈動脈進行小穿刺以插入導管。 VCD 的主要目的是快速有效地封閉穿刺部位，相較於傳統的手動壓迫方法，VCD 具有顯著的改進。傳統的手動壓迫方法不僅疼痛且耗時，需要醫護人員長時間壓迫，患者也需要長時間臥床休息。

VCD 市場受以下幾個關鍵因素驅動：

心血管疾病的盛行率不斷上升：這導致需要 VCD 的介入手術數量增加。

微創手術的興起：這些依靠導管介入的手術因為創傷小、恢復時間短等優點而變得越來越普遍。

技術進步：VCD 的技術創新，包括使用生物可吸收材料、改進的密封機制和自動部署系統，提高了其安全性和有效性。

改善患者預後：VCD 可以加快止血速度，降低出血和血腫等併發症的風險，加快患者的活動和出院速度，從而提高患者滿意度並降低醫療成本。

市場通常按設備類型細分：

主動閉合裝置：使用縫線或夾子物理閉合動脈切開術。

被動凝血計：使用膠原蛋白或凝膠等塞子或密封劑來促進凝血並密封穿孔。

外部止血裝置：貼在皮膚上以施加壓力並幫助止血。

推動全球血管閉合裝置市場的因素

血管閉合裝置 (VCD) 市場的主要促進因素包括心血管疾病盛行率的上升、介入手術的增加、微創手術需求的不斷成長以及器械本身的技術進步。這些因素共同推動了對有效、安全、高效的血管通路術後閉合解決方案的需求。

心血管疾病盛行率上升：心血管疾病 (CVD) 盛行率上升是 VCD 市場的主要驅動力。冠狀動脈疾病、周邊動脈疾病和中風等疾病在全球越來越常見，尤其是在中低收入國家。這種成長歸因於久坐不動的生活方式、不健康的飲食和人口老化等因素。隨著患有這些疾病的患者數量的增加，對血管造影術和血管成形術等診斷和治療程序的需求也在增加，這些程序需要快速安全地關閉穿刺部位的方法。 VCD 對於減少這些程序中的併發症至關重要，其使用量的增加與 CVD 負擔的增加直接相關。

介入性手術的興起：市場的主要驅動力之一是全球介入性心臟病學和放射學手術數量的不斷成長。這些手術，包括經皮冠狀動脈介入治療 (PCI) 和導管介入治療，已成為許多心血管疾病的標準治療手段。這些手術的大量使用將持續推動對 VCD 的強勁需求。與傳統的壓迫式手術相比，VCD 具有許多優勢，例如止血速度更快、患者活動時間更短以及血腫和出血等併發症風險更低。使用 VCD 帶來的手術效率也對醫療機構具有吸引力，進一步支持了 VCD 的廣泛應用。

微創手術需求不斷成長：微創手術需求不斷成長也是推動VCD市場發展的關鍵因素。與傳統的開放性手術相比，VCD切口較小、疼痛較少、住院時間較短，因此病患和醫護人員越來越青睞這類手術。 VCD是這一趨勢不可或缺的一部分，因為它提供了一種可靠有效的方法來封閉小導管穿刺點。 VCD的使用補充了微創手術的優勢，確保患者快速康復並降低術後併發症的風險，使其成為現代介入醫學的基石。

最後，血管閉合器械 (VCD) 的技術進步是市場成長的主要催化劑。技術創新正在推動更安全、更有效、更易於使用的器材。最新的 VCD 採用了先進材料，例如生物可吸收栓塞和密封劑，以及改進的閉合機制，例如夾子和縫線。這些新一代器械旨在適應更大的穿刺部位，這對於更複雜的手術至關重要。該領域研發的不斷增加以及監管機構的核准，正在推動市場發展，新產品的推出有助於改善患者治療效果並提高手術效率。

限制全球血管閉合裝置市場的因素

全球血管閉合裝置 (VCD) 市場有望實現成長，這得益於心血管手術的增多以及患者對更快康復的需求。然而，一些關鍵限制因素阻礙了其廣泛應用和擴張。這些挑戰包括：設備高成本、設備相關併發症的風險，以及需要高技能的醫療專業人員才能有效使用這些設備。

高成本：VCD 市場成長的最大障礙之一是設備本身的高昂成本。雖然 VCD 具有顯著優勢，包括加快患者康復時間和提高醫院效率，但其高昂的價格往往使其難以承受，尤其是在新興經濟體和預算有限的醫療保健系統中。每台 VCD 的價格高達數百美元，而且此類設備的報銷政策複雜甚至根本不存在，導致許多醫院和診所，尤其是在資源匱乏的地區，更傾向於採用手動按壓等傳統且成本更低的方法。儘管 VCD 具有明顯的臨床益處，但這些經濟障礙直接影響了市場滲透率，並限制了其成長潛力。

器械相關併發症風險：由於器械相關併發症風險，VCD 市場面臨巨大限制。雖然 VCD 旨在提高患者安全性和舒適度，但其使用並非沒有潛在隱患。血腫、假性動脈瘤、動靜脈瘺，甚至動脈阻塞等併發症都可能發生，但發生率因器械和病患因素而異。這些併發症可能導致患者嚴重患病，需要額外的醫療干預，甚至增加住院時間和費用，從而損害 VCD 的核心價值提案。此類不利事件的可能性，加上產品召回的歷史，阻礙了醫療保健提供者採用新設備，並產生了阻礙市場擴張的風險認知。

缺乏熟練的專業人員：血管閉合裝置的安全和成功部署在很大程度上取決於操作者的技能和經驗。缺乏熟練且訓練有素的醫療專業人員是市場發展的一大限制。與廣泛使用的手動按壓不同，VCD 需要專門的培訓和陡峭的學習曲線。由於缺乏專業知識而導致的使用不當會導致裝置故障，在最壞的情況下，還會增加患者併發症的風險。許多地區，尤其是那些醫療基礎設施尚未完善的地區，缺乏介入性心臟病專家和放射科醫生等能夠熟練使用此類先進裝置的專業人員。這種培訓差距限制了 VCD 的採用，使得醫院不願意投資其員工無法充分有效使用的技術。

The vascular closure devices (VCDs) market is a segment of the medical device industry focused on the development and distribution of devices used to achieve hemostasis, or the cessation of bleeding, after catheterization procedures. These procedures, such as angiography, angioplasty, and other cardiovascular interventions, involve making a small puncture, typically in the femoral or radial artery, to insert a catheter. The primary purpose of VCDs is to seal this puncture site quickly and effectively, offering a significant improvement over traditional manual compression methods. Manual compression is a painful, time consuming process that requires a healthcare professional to apply pressure for an extended period, followed by prolonged bed rest for the patient.

The VCD market is driven by several key factors:

Growing prevalence of cardiovascular diseases: This leads to an increased number of interventional procedures requiring a VCD.

Rise in minimally invasive procedures: These procedures, which rely on catheterization, are becoming more common due to their benefits of reduced trauma and faster recovery times.

Technological advancements: Innovations in VCDs, such as the use of bioabsorbable materials, improved sealing mechanisms, and automated deployment systems, are enhancing their safety and efficacy.

Improved patient outcomes: VCDs contribute to faster hemostasis, reduced risk of complications like bleeding and hematomas, and allow for earlier patient mobilization and discharge, leading to higher patient satisfaction and reduced healthcare costs.

The market is generally segmented by device type, including:

Active Approximators: These devices physically close the arteriotomy using sutures or clips.

Passive Approximators: These devices deploy a plug or sealant (like collagen or a gel) to promote clotting and seal the puncture.

External Hemostatic Devices: These are placed on the skin to apply pressure and aid in hemostasis.

Global Vascular Closure Devices Market Drivers

The key drivers of the vascular closure devices (VCD) market are the rising prevalence of cardiovascular diseases, the growing number of interventional procedures, the increasing demand for minimally invasive surgeries, and technological advancements in the devices themselves. These factors collectively contribute to a growing need for effective, safe, and efficient solutions for closing vascular access sites after procedures.

Rising Prevalence of Cardiovascular Diseases: The increasing prevalence of cardiovascular diseases (CVDs) is a primary driver of the VCD market. Conditions like coronary artery disease, peripheral artery disease, and stroke are becoming more common globally, especially in low and middle income countries. This rise is attributed to factors like sedentary lifestyles, unhealthy diets, and a growing aging population. As the number of patients with these conditions increases, so does the demand for diagnostic and therapeutic procedures, such as angiography and angioplasty, that require a quick and safe method to close the puncture site. VCDs are crucial in these procedures to reduce complications, and their increased use is directly correlated with the rising burden of CVDs.

Growing Number of Interventional Procedures: A significant market driver is the growing number of interventional cardiology and radiology procedures performed worldwide. These procedures, including percutaneous coronary interventions (PCIs) and catheter based interventions, have become the standard of care for many cardiovascular conditions. The high volume of these procedures creates a continuous and strong demand for VCDs. VCDs offer advantages over traditional manual compression, such as faster hemostasis (the stopping of blood flow), reduced time to patient ambulation, and a lower risk of complications like hematomas and bleeding. The procedural efficiency gained by using VCDs is also appealing to healthcare facilities, further fueling their adoption.

Increasing Demand for Minimally Invasive Procedures: The growing demand for minimally invasive procedures is another key factor propelling the VCD market. Patients and healthcare providers increasingly prefer these procedures because they involve smaller incisions, less pain, and shorter hospital stays compared to traditional open surgery. VCDs are an essential component of this trend, as they provide a reliable and efficient way to close the small puncture sites created by catheters. The use of VCDs complements the benefits of minimally invasive techniques by ensuring a fast recovery and reducing the risk of post procedural complications, making them a cornerstone of modern interventional medicine.

Technological Advancements in VCDs: Finally, technological advancements in vascular closure devices are a major catalyst for market growth. Innovation has led to the development of devices that are safer, more effective, and easier to use. Modern VCDs incorporate advanced materials, such as bioabsorbable plugs and sealants, as well as improved closure mechanisms, like clips and sutures. These new generations of devices are designed to handle larger access sites, which is essential for more complex procedures. The ongoing research and development in this sector, coupled with favorable regulatory approvals, continually introduces new products that offer better patient outcomes and procedural efficiency, driving the market forward.

Global Vascular Closure Devices Market Restraints

The global vascular closure devices (VCDs) market is poised for growth, driven by the increasing number of cardiovascular procedures and the demand for faster patient recovery. However, several key restraints impede its widespread adoption and expansion. These challenges include the high cost of devices, the risk of device related complications, and the need for highly skilled medical professionals to use them effectively.

High Cost of Devices: One of the most significant barriers to the growth of the VCD market is the high cost of the devices themselves. While VCDs offer considerable benefits, such as reduced patient recovery time and increased hospital efficiency, their price point often makes them unaffordable, particularly in developing economies or for healthcare systems with limited budgets. A single VCD can cost hundreds of dollars, and since reimbursement policies for these devices can be complex or non existent, many hospitals and clinics, especially in resource constrained regions, prefer to stick with traditional and much cheaper methods like manual compression. This financial hurdle directly impacts the market's penetration and limits its growth potential, despite the clear clinical advantages VCDs offer.

Risk of Device Related Complications: The market faces a significant restraint from the risk of device related complications. While VCDs are designed to enhance patient safety and comfort, their use is not without potential pitfalls. Complications like hematoma, pseudoaneurysm, arteriovenous fistula, and even arterial occlusion can occur, though at varying rates depending on the device and patient factors. These complications can lead to serious patient morbidity, require additional medical intervention, and even increase hospital stay and costs, which undermines the core value proposition of VCDs. This potential for adverse events, coupled with a history of product recalls, can make healthcare providers hesitant to adopt new devices, creating a perception of risk that hinders market expansion.

Lack of Skilled Professionals: The successful and safe deployment of vascular closure devices is highly dependent on the skill and experience of the operator. The lack of highly skilled and adequately trained medical professionals is a major restraint on the market. Unlike manual compression, which is a widely practiced technique, VCDs require specific training and a steep learning curve. Improper use due to a lack of expertise can lead to device failure or, worse, increase the risk of complications for the patient. In many regions, particularly those with emerging healthcare infrastructures, there's a shortage of specialists like interventional cardiologists and radiologists who are proficient in using these advanced devices. This training gap limits the adoption of VCDs, as hospitals are reluctant to invest in technology that their staff is not fully equipped to use effectively.

Global Vascular Closure Devices Market: Segmentation Analysis

The Global Vascular Closure Devices Market is Segmented on the basis of Type, Access, End User, And Geography.

Vascular Closure Devices Market, By Type

Passive Approximators

Active Approximators

External Hemostatic Devices

Based on Type, the Vascular Closure Devices Market is segmented into Passive Approximators, Active Approximators, and External Hemostatic Devices. At VMR, we observe that Active Approximators dominate the market, accounting for the largest share due to their superior efficacy in ensuring rapid hemostasis, reduced complication rates, and faster patient ambulation compared to manual compression methods. Their adoption is particularly strong in North America and Europe, where high procedural volumes of angiography and interventional cardiology, combined with favorable reimbursement structures, are driving growth. Increasing demand for minimally invasive procedures and the shift toward outpatient catheterization labs further support their uptake. Technological advancements, including suture and clip based mechanisms, have significantly improved patient outcomes, making them the preferred choice among interventional cardiologists and vascular surgeons.

According to industry estimates, Active Approximators contribute to nearly 50-55% of total market revenue, with a CAGR of around 7% expected through the forecast period, reflecting strong demand from hospitals and specialty clinics. The second most dominant segment, Passive Approximators, plays a crucial role in the market by catering to healthcare providers seeking cost effective alternatives without compromising procedural safety. Passive devices, such as collagen based plugs and sealants, are witnessing robust adoption in Asia Pacific and Latin America, where rising cardiovascular disease prevalence and expanding access to advanced healthcare infrastructure are fueling growth. With an estimated 30-35% revenue contribution, this segment benefits from increasing usage in low resource settings and in procedures where suture based devices may not be necessary, thereby supporting the market's overall expansion.

External Hemostatic Devices represent a smaller yet important segment, largely serving as supportive tools in cases where internal vascular closure is not feasible or when additional hemostatic control is required. While their adoption remains niche, particularly in outpatient and emergency settings, ongoing innovation in hemostatic patches and compression devices positions them for steady growth, especially in emerging markets. Overall, the Vascular Closure Devices Market reflects a clear dominance of Active Approximators, strong cost driven adoption of Passive Approximators, and the niche but evolving role of External Hemostatic Devices, underscoring a balanced yet innovation driven competitive landscape.

Vascular Closure Devices Market, By Access

Femoral Access

Radial Access

Based on Access, the Vascular Closure Devices Market is segmented into Femoral Access,Radial Access. At VMR, we observe that Femoral Access is the clear dominant subsegment today - driven by the historically higher procedural volume of transfemoral diagnostic and interventional procedures (angiography, PCI, large bore structural interventions), broad clinician familiarity, and an extensive installed base of femoral specific closure technologies; industry reports indicate femoral access accounted for the vast majority of the access type market (reported ~80-84% share in recent analyses), underpinning the segment's outsized revenue contribution and steady unit demand. This dominance is supported by data showing the overall VCD market expanding at mid single digit CAGRs (VMR and peer reports commonly state a market CAGR in the ~6-7% range through the late 2020s) and by North America's continued leadership in adoption and revenue, while established hospital networks in Europe and growing procedure volumes in Asia Pacific sustain femoral device sales. Key drivers include rising global cardiovascular intervention volumes, payer and hospital focus on reducing time to hemostasis and length of stay, regulatory approvals for new femoral plat-forms, and supplier consolidation that favors broad, femoral focused portfolios.

Radial Access is the second most dominant subsegment: while its current revenue base is smaller than femoral's, radial is the fastest growing access route driven by shifting clinician preference for radial first coronary angiography/PCI (lower vascular complication profile, faster ambulation), higher adoption rates in interventional cardiology centers in Europe and parts of Asia, and device innovation tailored for smaller sheath sizes - many forecasts cite higher radial CAGR versus femoral even as radial's absolute share remains below femoral. Regional strength for radial is strongest in Europe and select APAC markets where radial first protocols are increasingly standard practice.

Remaining subsegments (operationally, niche procedural variants and emerging large bore/structural closure adaptations) play a supporting but strategic role: they enable suppliers to address specialized high value procedures (TAVR, EVAR) and act as the innovation pipeline for next generation hemostasis solutions. Collectively, these niches offer upside (clinical trials and reimbursement shifts could widen adoption) even as femoral remains the revenue anchor and radial the growth engine for the VCD market.

Vascular Closure Devices Market, By End User

Acute Care Facilities

Hospitals

Clinics

Others

Based on End User, the Vascular Closure Devices Market is segmented into Acute Care Facilities, Hospitals, Clinics, and Others. At VMR, we observe that Hospitals represent the dominant subsegment, accounting for the largest share of the market due to their high patient inflow, advanced infrastructure, and widespread adoption of vascular closure devices for interventional cardiology and radiology procedures. Hospitals benefit from favorable reimbursement policies in North America and Europe, while rising investments in healthcare infrastructure across Asia Pacific further strengthen their position. According to industry data, hospitals capture well over 45-50% of the total market revenue, supported by the growing prevalence of cardiovascular diseases, increasing procedural volumes such as angioplasty and catheterization, and the integration of advanced minimally invasive closure technologies.

Moreover, hospitals are key adopters of automated and digitalized closure systems, aligning with industry trends of improving procedural efficiency and reducing complication rates, which further cements their dominance. The second most dominant subsegment is Acute Care Facilities, which are witnessing strong growth driven by the increasing demand for emergency and specialized care in cardiovascular interventions. With a CAGR projected in the high single digits, this segment benefits from rapid expansion in urban centers across Asia Pacific and Latin America, where demand for immediate intervention in trauma and acute cardiac cases is rising. Acute care facilities also play a critical role in regions with decentralized healthcare systems, offering faster access to vascular closure solutions in urgent scenarios.

Clinics and Others occupy a smaller yet significant portion of the market, serving as complementary channels that support outpatient and day care interventional procedures. Clinics, in particular, are gaining traction in developed economies where patients prefer less invasive settings with faster discharge, while the "Others" category-including ambulatory surgical centers and specialty care providers-holds niche potential as healthcare delivery models continue shifting toward cost effective, decentralized care. Although their current market share is modest compared to hospitals, these subsegments are expected to show steady adoption in the forecast period, especially with the rise of outpatient cardiovascular interventions and the emphasis on reducing overall healthcare costs.

Vascular Closure Devices Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

The global vascular closure devices (VCD) market is experiencing significant growth, driven by the increasing prevalence of cardiovascular diseases, the rising number of interventional procedures such as angioplasty and angiography, and a growing preference for minimally invasive treatments. VCDs are designed to seal the puncture site in a blood vessel after a catheter based procedure, offering advantages over manual compression like faster hemostasis, reduced complications, and improved patient comfort. The market's geographical landscape is diverse, with varying dynamics, growth drivers, and trends across different regions, influenced by healthcare infrastructure, economic development, and demographic shifts.

United States Vascular Closure Devices Market

The United States holds a dominant position in the global VCD market, accounting for a significant share. This is primarily attributed to a highly developed healthcare system, high healthcare expenditure, and the presence of major market players.

Dynamics: The U.S. market is characterized by a high volume of interventional cardiology procedures, a strong emphasis on technological innovation, and favorable reimbursement policies. The shift towards ambulatory surgical centers (ASCs) is a key trend, as these facilities prioritize patient comfort and faster discharge, which is facilitated by the use of VCDs.

Key Growth Drivers: The high prevalence of cardiovascular diseases, an aging population, and the widespread adoption of advanced vascular closure devices in hospitals and ASCs are the main drivers. The continuous introduction of novel devices with improved features, such as bioabsorbable materials and better sealing mechanisms, also fuels market growth.

Current Trends: There is a notable trend towards the adoption of large bore vascular closure devices, which are essential for procedures like transcatheter aortic valve implantation (TAVI). Furthermore, the market is seeing a focus on devices for radial access procedures, though femoral access still holds the largest market share.

Europe Vascular Closure Devices Market

Europe is the second largest market for vascular closure devices. The market's growth is steady and supported by a combination of factors, including a well established healthcare system and a growing demand for less invasive procedures.

Dynamics: The European market is mature, with key countries like Germany, France, and the UK leading the way. The market is influenced by government healthcare policies and the aging population, which contributes to a higher incidence of cardiovascular conditions.

Key Growth Drivers: The increasing prevalence of cardiovascular diseases, a growing geriatric population, and the rising adoption of minimally invasive procedures are the primary drivers. Strategic activities by manufacturers, such as securing CE Mark certification for new products, are also crucial for market expansion in the region.

Current Trends: There is a steady move towards adopting advanced technologies, although there can be variations in adoption rates across different countries due to differences in healthcare budgets and regulatory processes. The market is also seeing a growing preference for passive closure devices, which are popular for their simplicity and lower complication rates.

Asia Pacific Vascular Closure Devices Market

The Asia Pacific region is the fastest growing market for VCDs. This rapid growth is driven by a combination of improving healthcare infrastructure and a large patient population.

Dynamics: The market is dynamic and characterized by significant growth in emerging economies like China and India. Economic growth has led to increased healthcare spending and improved access to advanced medical treatments.

Key Growth Drivers: The high prevalence of cardiovascular diseases, a massive population base, and rapid urbanization are key factors. Additionally, rising disposable incomes, and increasing awareness about modern medical technologies are propelling the market.

Current Trends: Japan holds a dominant position in the region, largely due to its aging population and strong acceptance of technological advancements. However, China and India are emerging as major contributors due to government initiatives to modernize healthcare infrastructure and a rising demand for diagnostic and interventional services. The market is also benefiting from a growing number of clinical trials and research activities in the region.

Latin America Vascular Closure Devices Market

The Latin American market for vascular closure devices is experiencing substantial expansion, albeit from a smaller base compared to North America and Europe.

Dynamics: The market is characterized by a rising burden of cardiovascular diseases, driven by factors such as a growing geriatric population and an increase in risk factors like diabetes and obesity.

Key Growth Drivers: The demand for minimally invasive interventions is increasing, which directly boosts the need for VCDs. Additionally, governments in various Latin American countries are investing in healthcare infrastructure development, improving access to advanced medical devices.

Current Trends: Brazil is a key country in the region, projected to register a high growth rate. The market is also seeing an increase in awareness regarding peripheral vascular diseases, leading to a higher rate of diagnosis and treatment, and thus a greater demand for a variety of vascular devices, including VCDs.

Middle East & Africa Vascular Closure Devices Market

The Middle East & Africa (MEA) market for vascular closure devices is still in its nascent stage but offers significant future opportunities.

Dynamics: The market is influenced by the increasing prevalence of cardiovascular diseases and chronic conditions such as diabetes and hypertension. While the market is relatively small, ongoing urbanization and healthcare development are paving the way for future growth.

Key Growth Drivers: Investments in healthcare infrastructure, particularly in the Gulf Cooperation Council (GCC) countries, are a major driver. The rise in medical tourism and improving access to specialized care also contribute to market growth.

Current Trends: The MEA market remains stable, with ongoing healthcare development presenting long term opportunities. The demand for effective treatment options for cardiovascular diseases is increasing, which is expected to drive the adoption of VCDs in the coming years.

Key Players

The "Global Vascular Closure Devices Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Abbott Laboratories, Medtronic Plc, Transluminal Technologies LLC, Cardinal Health, Inc., Vascular Closure Systems, Inc., Vivasure Medical Ltd., Vasorum Ltd., Morris Innovative Inc., Cardiva Medical, Inc., Terumo Corporation, and Essential Medical, Inc.

1 INTRODUCTION OF GLOBAL VASCULAR CLOSURE DEVICES MARKET

1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL VASCULAR CLOSURE DEVICES MARKET OUTLOOK

4.1 OVERVIEW
4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.2 RESTRAINTS
- 4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL VASCULAR CLOSURE DEVICES MARKET, BY TYPE

5.1 OVERVIEW
5.2 ACTIVE APPROXIMATORS
5.3 PASSIVE APPROXIMATORS
5.4 EXTERNAL HOMOSTATICDEVICES

6 GLOBAL VASCULAR CLOSURE DEVICES MARKET, BY ACCESS

6.1 OVERVIEW
6.2 FEMORAL ACCESS
6.3 RADIAL ACCESS

7 GLOBAL VASCULAR CLOSURE DEVICES MARKET, BY END USER

7.1 OVERVIEW
7.2 ACUTE CARE FACILITIES
7.3 HOSPITALS
7.4 CLINICS
7.5 OTHERS

8 GLOBAL VASCULAR CLOSURE DEVICES MARKET, BY GEOGRAPHY

8.1 OVERVIEW
8.2 NORTH AMERICA
- 8.2.1 U.S.
- 8.2.2 CANADA
- 8.2.3 MEXICO
8.3 EUROPE
- 8.3.1 GERMANY
- 8.3.2 U.K.
- 8.3.3 FRANCE
- 8.3.4 REST OF EUROPE
8.4 ASIA PACIFIC
- 8.4.1 CHINA
- 8.4.2 JAPAN
- 8.4.3 INDIA
- 8.4.4 REST OF ASIA PACIFIC
8.5 REST OF THE WORLD
- 8.5.1 LATIN AMERICA
- 8.5.2 MIDDLE EAST AND AFRICA